IN THE CLAIMS:

Please amend the claims as shown in the following listing of claims. This listing of claims will replace all prior versions, and listings, of claims in the application:

1-26 (Cancelled)

- 27. (Currently Amended) A method for <u>achieving full</u> occlu<u>sion[[ding]] of</u> a vascular vessel, comprising delivering to the vessel an embolization device comprising <u>a harvested</u> submucosal tissue so as to occlude and cause a <u>full occlusion and</u> full blockage of the vascular vessel.
- 28. (Original) The method of claim 27, wherein the embolization devices comprises a coil.
 - 29. (Original) The method of claim 27, wherein the submucosa is porcine submucosa.
- 30. (Original) The method of claim 27, wherein the embolization device comprises at least one sheet of submucosa.
- 31. (Previously Presented) The method of claim 27, wherein the device comprises a particulate material comprising submucosa.
- 32. (Currently Amended) A method for achieving full occlusion[[ding]] of a vascular vessel of a patient, comprising delivering to the vessel an embolization device comprising a harvested remodelable collagenous extracellular matrix biomaterial so as to occlude and cause a full occlusion and full blockage of the vascular vessel, wherein the harvested remodelable collagenous extracellular matrix biomaterial is effective to promote a healing response in an area of the vascular vessel occluded with the harvested remodelable collagenous extracellular matrix biomaterial.

- 33. (Previously Presented) The method of claim 32, wherein the biomaterial comprises submucosa.
 - 34. (Previously Presented) The method of claim 32, wherein the device comprises a coil.
- 35. (Previously Presented) The method of claim 32, wherein the biomaterial comprises porcine submucosa.
- 36. (Previously Presented) The method of claim 32, wherein the device comprises at least one sheet of the remodelable collagenous extracellular matrix biomaterial.
- 37. (Previously Presented) The method of claim 32, wherein a pharmacologic agent is disposed on the biomaterial.
- 38. (Previously Presented) The method of claim 32, wherein the biomaterial comprises at least one of a brush-like, braided, branched, coil, cubic, cylindrical, helical, injectable, layered, randomized, sheet-like, spherical, and tubular component.
- 39. (Previously Presented) The method of claim 32, wherein the biomaterial further comprises at least one of a growth factor, protein, proteoglycan, glycoprotein, glycosaminoglycan, physiological compatible mineral, antibiotic, chemotherapeutic agent, enzyme, pharmaceutical, taxol, taxol derivative, genetic material, and hormone.
- 40. (Previously Presented) The method of claim 32, wherein the biomaterial comprises a material selected from submucosa, pericardium, basement membrane, and amniotic membrane.
- 41. (Previously Presented) The method of claim 32, wherein the biomaterial also comprises a radiopaque marker.
 - 42. (Previously Presented) The method of claim 32, wherein the biomaterial is injectable.

- 43. (Previously Presented) The method of claim 32, wherein the biomaterial is in comminuted form.
- 44. (Previously Presented) The method of claim 33, wherein the biomaterial is in comminuted form.